Evidence map›Paper›PMID 31092698›Full record

ReviewBioscience reports2019

Autologous activated platelet-rich plasma injection into adult human ovary tissue: molecular mechanism, analysis, and discussion of reproductive response.

E Scott Sills, Samuel H Wood

3 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Bioscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 48 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 5 pooled it
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04797377 nacompletednot on this mapstarted 2021, after this paper: background citation

Effects of Autologous Intraovarian Platelet Rich Plasma in Women With Poor Ovarian Response

TypeinterventionalSponsorNadezhda Women's Health HospitalRan2021 to 2021Enrolled66ConditionsPoor Ovarian ReserveArmsAutologous ovarian PRP injection
NCT05279560 naactive not recruitingnot on this mapstarted 2022, after this paper: background citation

The Efficacy and Safety of Intra-ovarian PRP Injection Within a Prospective, Single-blinded, Placebo-controlled, Randomized, Clinical Superiority Trial in Subjects With Low Ovarian Reserve/Expected Poor Ovarian Response

TypeinterventionalSponsorUniversity of LuebeckRan2022 to 2030Enrolled114ConditionsPremature Ovarian Insufficiency, Infertility, Female, Sterility, Female, PRPArmsautologous PRP (platelet rich plasma), Saline solution (NaCL) Injection
NCT07376460 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Biological and Proteomic Characterisation of Platelet-rich Plasma (PRP) Before and After Mobilisation of Haematopoietic Stem Cells in Peripheral Blood From Women With Low Ovarian Response (Low Responders) and in Vitro Evaluation in Human Ovarian Cell Models

TypeobservationalSponsorInstituto Valenciano de Infertilidad, IVI AlicanteRan2026 to 2026Enrolled10ConditionsPoor Ovarian Response, Ovarian ReactivationArmsPlatelet Rich Plasma + BMDSCs mobilization
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 5 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Autologous platelet-rich plasma for assisted reproduction.The Cochrane database of systematic reviews · 2024
    Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Application of Autologous Platelet-Rich Plasma-Supplemented Medium PromotesInternational journal of fertility & sterility · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

E Scott SillsGen 5 Fertility Center, Office for Reproductive Research, Center for Advanced Genetics; San Diego, CA, U.S.A. drsills@CAGivf.com.ORCID 0000-0001-7334-1031
Samuel H WoodGen 5 Fertility Center, Office for Reproductive Research, Center for Advanced Genetics; San Diego, CA, U.S.A.
University of San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In clinical infertility practice, one intractable problem is low (or absent) ovarian reserve which in turn reflects the natural oocyte depletion associated with advancing maternal age. The number of available eggs has been generally thought to be finite and strictly limited, an entrenched and largely unchallenged tenet dating back more than 50 years. In the past decade, it has been suggested that renewable ovarian germline stem cells (GSCs) exist in adults, and that such cells may be utilized as an oocyte source for women seeking to extend fertility. Currently, the issue of whether mammalian females possess such a population of renewable GSCs remains unsettled. The topic is complex and even agreement on a definitive approach to verify the process of 'ovarian rescue' or 're-potentiation' has been elusive. Similarities have been noted between wound healing and ovarian tissue repair following capsule rupture at ovulation. In addition, molecular signaling events which might be necessary to reverse the effects of reproductive ageing seem congruent with changes occurring in tissue injury responses elsewhere. Recently, clinical experience with such a technique based on autologous activated platelet-rich plasma (PRP) treatment of the adult human ovary has been reported. This review summarizes the present state of understanding of the interaction of platelet-derived growth factors with adult ovarian tissue, and the outcome of human reproductive potential following PRP treatment.

Indexed as

AdultAgingFemaleFertilityHumansOocytesOvarian FollicleOvarian ReservePlatelet-Rich PlasmaReproductionagingfertilitymenopauseovaryreproduction

Identifiers

PMID31092698
PMCPMC6549090
OpenAlexW2945517418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.